[
    [
        {
            "time": "",
            "original_text": "葛兰勇进，高瓴撤退，CXO 困境下的“旗手”与“叛徒”",
            "features": {
                "keywords": [
                    "葛兰",
                    "高瓴",
                    "CXO",
                    "困境",
                    "旗手",
                    "叛徒"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "葛兰勇进，高瓴撤退，CXO 困境下的“旗手”与“叛徒”",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 10,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "CRO行业三季报总结：公募高配，估值高企",
            "features": {
                "keywords": [
                    "CRO",
                    "三季报",
                    "公募",
                    "估值",
                    "高配",
                    "高企"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CRO行业三季报总结：公募高配，估值高企",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "预见2022：《2021年中国医药研发外包(CRO)行业全景图谱》(附市场现状、竞争格局和发展趋势等)",
            "features": {
                "keywords": [
                    "2022",
                    "2021",
                    "医药",
                    "CRO",
                    "行业",
                    "全景图谱",
                    "市场现状",
                    "竞争格局",
                    "发展趋势"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CRO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "预见2022：《2021年中国医药研发外包(CRO)行业全景图谱》(附市场现状、竞争格局和发展趋势等)",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 10,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "盘点 | 上海医药、罗欣药业、烨辉医药、翰森制药等多家公司引进新药，它们有何亮点？",
            "features": {
                "keywords": [
                    "上海医药",
                    "罗欣药业",
                    "烨辉医药",
                    "翰森制药",
                    "新药",
                    "亮点"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "盘点 | 上海医药、罗欣药业、烨辉医药、翰森制药等多家公司引进新药，它们有何亮点？",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]